Literature DB >> 27141363

IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?

Jakub Tomala1, Marek Kovar1.   

Abstract

The in vivo biological activity of IL-2 can be dramatically increased by complexing with anti-IL-2 mAb. Moreover, IL-2/anti-IL-2 mAb immunocomplexes selectively stimulate different subsets of immune cells, depending on the clone of anti-IL-2 mAb that is used. Thus, IL-2/S4B6 mAb complexes strongly stimulate CD122high populations, namely NK and memory CD8+ T cells. They also intermediately stimulate Treg cells. Conversely, IL-2/JES6.1 mAb immunocomplexes have no stimulatory activity for CD122high populations. However, they potently and highly selectively stimulate CD25+ cells (i.e., Treg and activated T cells). IL-2/S4B6 mAb immunocomplexes have also been shown to possess antitumor activity in various mouse tumor models.

Entities:  

Keywords:  Anti-IL-2 mAb; IL-2; cancer immunotherapy; immunocomplexes; selective stimulatory activity

Year:  2015        PMID： 27141363      PMCID： PMC4839359          DOI： 10.1080/2162402X.2015.1102829

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  83 in total

1.  IL-2 complex treatment can protect naive mice from bacterial and viral infection.

Authors:  Sara E Hamilton; Jason M Schenkel; Adovi D Akue; Stephen C Jameson
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

Review 2.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.

Authors:  Carsten Krieg; Sven Létourneau; Giuseppe Pantaleo; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

Review 5.  Gene-based vaccines and immunotherapeutics.

Authors:  Margaret Liu; Bruce Acres; Jean-Marc Balloul; Nadine Bizouarne; Stephane Paul; Philippe Slos; Patrick Squiban
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-27       Impact factor: 11.205

6.  Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Authors:  Onur Boyman; Marek Kovar; Mark P Rubinstein; Charles D Surh; Jonathan Sprent
Journal:  Science       Date:  2006-02-16       Impact factor: 47.728

Review 7.  Natural killer cells.

Authors:  R B Herberman
Journal:  Annu Rev Med       Date:  1986       Impact factor: 13.739

8.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

9.  In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.

Authors:  Jakub Tomala; Helena Chmelova; Tomas Mrkvan; Blanka Rihova; Marek Kovar
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

10.  The interleukin 2 receptor. Functional consequences of its bimolecular structure.

Authors:  H M Wang; K A Smith
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307
View more
  10 in total

Review 1.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

2.  CD25-Targeted IL-2 Signals Promote Improved Outcomes of Influenza Infection and Boost Memory CD4 T Cell Formation.

Authors:  Fahmida Alam; Ayushi Singh; Valeria Flores-Malavet; Stewart Sell; Andrea M Cooper; Susan L Swain; K Kai McKinstry; Tara M Strutt
Journal:  J Immunol       Date:  2020-05-06       Impact factor: 5.422

Review 3.  Cancer immunotherapy beyond immune checkpoint inhibitors.

Authors:  Julian A Marin-Acevedo; Aixa E Soyano; Bhagirathbhai Dholaria; Keith L Knutson; Yanyan Lou
Journal:  J Hematol Oncol       Date:  2018-01-12       Impact factor: 17.388

4.  Immunomodulatory effects of soluble CD5 on experimental tumor models.

Authors:  Inês T Simões; Fernando Aranda; Esther Carreras; Maria Velasco-de Andrés; Sergi Casadó-Llombart; Vanesa G Martinez; Francisco Lozano
Journal:  Oncotarget       Date:  2017-11-20

5.  CD122-targetted IL-2 signals cause acute and selective apoptosis of B cells in Peyer's Patches.

Authors:  Ayushi Singh; Kunal Dhume; Joanne D Tejero; Tara M Strutt; K Kai McKinstry
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 6.  Interleukin-6 at the Host-Tumor Interface: STAT3 in Biomolecular Condensates in Cancer Cells.

Authors:  Pravin B Sehgal
Journal:  Cells       Date:  2022-03-30       Impact factor: 6.600

7.  Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration.

Authors:  Rui Guan; Qiong Lyu; Anqi Lin; Junyi Liang; Weimin Ding; Manming Cao; Peng Luo; Jian Zhang
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

Review 8.  Next generation of immune checkpoint therapy in cancer: new developments and challenges.

Authors:  Julian A Marin-Acevedo; Bhagirathbhai Dholaria; Aixa E Soyano; Keith L Knutson; Saranya Chumsri; Yanyan Lou
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388

9.  Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections.

Authors:  Isaac J Jensen; Christina S Winborn; Micaela G Fosdick; Peng Shao; Mikaela M Tremblay; Qiang Shan; Sandeep Kumar Tripathy; Christopher M Snyder; Hai-Hui Xue; Thomas S Griffith; Jon C Houtman; Vladimir P Badovinac
Journal:  PLoS Pathog       Date:  2018-10-31       Impact factor: 6.823

Review 10.  Escape or Fight: Inhibitors in Hemophilia A.

Authors:  Simone Merlin; Antonia Follenzi
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.